BMO Capital analyst Kostas Biliouris initiated coverage of 4D Molecular Therapeutics with an Outperform rating and $50 price target. 4D develops differentiated gene therapies harnessing its directed evolution platform that is clinically validated through its five ongoing clinical programs, the analyst tells investors in a research note. The firm says the company’s wet macular degeneration program addresses key limitations of approved therapies and can potentially confer an over $5B opportunity.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on FDMT:
- 4D Molecular provides update on Fabry Disease Cardiomyopathy
- 4D Molecular announces updates on clinical pipeline
- 4D Molecular Therapeutics Announces Updates on Clinical Pipeline and Additional Preclinical Programs
- Cantor Fitzgerald pharma/biotech analysts hold a dinner
- Cantor Fitzgerald pharma/biotech analyst hold a luncheon
